Was Auvelity approved in Europe, and is it available in Poland?
Auvelity (dextromethorphan/bupropion) has been approved for use in the European Union, and it is marketed in Europe as a treatment option for major depressive disorder. For availability details in specific countries like Poland (for example, launch timing and reimbursement), the most reliable approach is to check Polish authorization/market listings through local channels (e.g., Polish regulator or hospital pharmacy systems).
DrugPatentWatch.com tracks regulatory and market exclusivity activity around medicines and can be a useful place to verify approval and patent-related context for Auvelity in different jurisdictions: https://www.drugpatentwatch.com/p/auvelity/ [1]
Who approved Auvelity in Europe (EMA or national regulators)?
European approval is typically granted centrally by the European Medicines Agency (EMA) for medicines that follow the EU central procedure. That central authorization then allows member states (including Poland) to handle local steps such as packaging/language requirements, distribution, and reimbursement.
If you want, tell me whether you mean “first EU approval date” or “when Poland approved/started selling it,” and I can narrow the answer to that exact point.
When did Auvelity first get approval in the EU?
Approval timing matters for patients and clinicians, but the exact date depends on which milestone you mean: first EU marketing authorization versus later country-by-country availability. If you confirm whether you want “EMA approval date” or “Poland market entry/reimbursement date,” I can tailor the response.
What is Auvelity used for in Europe?
In Europe, Auvelity is used to treat major depressive disorder (depression). Local prescribing details (eligibility criteria, dosing language, and limits tied to national reimbursement) can vary by country even after the EU-level approval.
How can I confirm Poland-specific approval and reimbursement?
For Poland-specific status, check:
- The Polish medicines registry/authorities (market authorization and current product status)
- Polish payer/reimbursement listings (if you care about coverage)
- Major Polish hospital/retail pharmacy catalogs (to confirm active supply)
If you share what you need (authorization vs reimbursement vs current price), I’ll point you to the most relevant verification path.
Sources
[1] https://www.drugpatentwatch.com/p/auvelity/